A multi-site randomized trial found that the suicide-prevention app OTX202 reduced repeat suicide attempts by 58% and sustained lower suicidal ideation through 24 weeks, especially in high-risk patients with prior attempts. A phase 3 trial showed canagliflozin significantly improved glycemic control in children and adolescents with type 2 diabetes, with safety comparable to adults. Finally, the SWIFT-SEG liquid biopsy detected multiple myeloma tumor cells in over 90% of cases, offering a less invasive alternative to bone marrow biopsies for diagnosis, monitoring, and precision treatment.